Elisabeth Miot-Noirault Selected Research

Melanins (Melanin)

4/2022	Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol.
11/2019	Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.
11/2018	Radiation dosimetry of [131 I]ICF01012 in rabbits: Application to targeted radionuclide therapy for human melanoma treatment.
1/2017	Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.
3/2016	Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy.
3/2015	Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma.
2/2015	Development and Preliminary Evaluation of TFIB, a New Bimodal Prosthetic Group for Bioactive Molecule Labeling.
1/2015	[¹²³I]ICF01012 melanoma imaging and [¹³¹I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models.
8/2014	Evaluation of two (125)I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma.
5/2014	Synthesis and Biological Evaluation of New Quinoxaline Derivatives of ICF01012 as Melanoma-Targeting Probes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elisabeth Miot-Noirault Research Topics

Disease

34	Neoplasms (Cancer) 06/2022 - 07/2004
25	Melanoma (Melanoma, Malignant) 04/2022 - 07/2005
12	Chondrosarcoma 06/2022 - 09/2009
7	Hypoxia (Hypoxemia) 01/2022 - 07/2013
5	Inflammation (Inflammations) 01/2022 - 02/2012
5	Osteoporosis 11/2015 - 02/2012
4	Osteoarthritis 01/2022 - 05/2009
3	Pain (Aches) 01/2022 - 05/2015
3	Neoplasm Metastasis (Metastasis) 01/2015 - 01/2014
2	Rheumatoid Arthritis 01/2022 - 05/2015
2	Hypersensitivity (Allergy) 01/2022 - 12/2021
2	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2021
2	Colorectal Neoplasms (Colorectal Cancer) 12/2021 - 03/2017
2	Extraskeletal Myxoid Chondrosarcoma 01/2021 - 01/2020
2	Triple Negative Breast Neoplasms 01/2020 - 01/2019
2	Breast Neoplasms (Breast Cancer) 01/2020 - 07/2013
1	Cholangiocarcinoma 06/2022
1	Glioma (Gliomas) 06/2022
1	Tics (Tic) 01/2022
1	Low Back Pain (Lumbago) 01/2022
1	Edema (Dropsy) 01/2022
1	Synovitis 01/2022
1	Hyperalgesia 01/2022
1	Channelopathies 12/2021
1	Peripheral Nervous System Diseases (PNS Diseases) 12/2021
1	Circulating Neoplastic Cells 11/2019

Drug/Important Bio-Agent (IBA)

18	Melanins (Melanin)IBA 04/2022 - 07/2005
15	Radioisotopes (Radionuclides)IBA 04/2022 - 11/2008
11	Proteoglycans (Proteoglycan)IBA 01/2021 - 05/2009
10	N- (2- diethylaminoethyl)- 6- iodoquinoxaline- 2- carboxamideIBA 04/2022 - 11/2008
9	LigandsIBA 01/2021 - 01/2009
7	Pharmaceutical PreparationsIBA 01/2022 - 07/2013
7	ProdrugsIBA 01/2022 - 05/2011
6	Ammonium CompoundsIBA 01/2020 - 08/2012
3	benzamideIBA 04/2022 - 11/2011
3	DNA (Deoxyribonucleic Acid)IBA 11/2017 - 07/2004
3	Peptides (Polypeptides)IBA 02/2015 - 11/2011
3	Antineoplastic Agents (Antineoplastics)IBA 05/2014 - 07/2004
2	EnzymesIBA 06/2022 - 06/2016
2	pyridineIBA 01/2022 - 09/2012
2	Tyrosine (L-Tyrosine)FDA Link 01/2022 - 07/2005
2	Freund's AdjuvantIBA 01/2022 - 05/2015
2	fluoromisonidazoleIBA 01/2021 - 01/2020
2	ICF05016IBA 01/2021 - 01/2020
2	Aggrecans (Aggrecan)IBA 01/2020 - 10/2018
2	azomycinIBA 01/2020 - 11/2017
2	Alkylating AgentsIBA 11/2017 - 07/2004
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 03/2017 - 11/2014
2	Iodine-125IBA 09/2016 - 05/2013
2	Biological ProductsIBA 09/2016 - 05/2014
2	IodineIBA 03/2016 - 11/2013
2	AntioxidantsIBA 11/2015 - 08/2014
2	Proteins (Proteins, Gene)FDA Link 10/2014 - 07/2013
2	AcridinesIBA 08/2014 - 12/2011
2	QuinoxalinesIBA 05/2014 - 08/2009
2	N- (2- (diethylamino)ethyl)- 2- iodobenzamideIBA 01/2014 - 07/2005
2	N- (2- (diethylamino)ethyl)- 4- iodobenzamideIBA 11/2011 - 07/2005
2	4- tert- butyl- (3- (2- chloroethyl)ureido)benzeneIBA 11/2005 - 07/2004
1	SolutionsIBA 06/2022
1	isocitric acid (isocitrate)IBA 06/2022
1	Oxidoreductases (Dehydrogenase)IBA 06/2022
1	Organotin CompoundsIBA 01/2022
1	hydroxide ionIBA 01/2022
1	Amino Acids FDA Link 01/2022
1	copper(I) triflateIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Analgesics (Analgesic Drugs)IBA 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022
1	Docetaxel (Taxotere)FDA Link 01/2022
1	Secretory Phospholipases A2IBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	TH 302IBA 01/2022
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2022
1	Nerve Growth Factor (NGF)IBA 01/2022
1	fibroblast growth factor 18IBA 01/2022
1	trkA ReceptorIBA 01/2022
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2022
1	Acid Sensing Ion ChannelsIBA 01/2022
1	Ion Channels (Ion Channel)IBA 12/2021
1	entinostat (MS 275)IBA 12/2021
1	Potassium Channels (Potassium Channel)IBA 12/2021
1	Histone Deacetylase InhibitorsIBA 12/2021
1	Histone Deacetylases (Histone Deacetylase)IBA 12/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2021
1	AntigensIBA 01/2021
1	APTIBA 01/2021
1	N-(triethylammonium)-3-propyl(15)ane-N5IBA 01/2021
1	Contrast MediaIBA 01/2021
1	Caspase 3 (Caspase-3)IBA 01/2020
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2020
1	Epirubicin (Ellence)FDA LinkGeneric 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2020
1	imidazoleIBA 01/2020
1	procaine isothiocyanate (PRIT)IBA 01/2019

Therapy/Procedure

23	Therapeutics 04/2022 - 11/2008
6	Drug Therapy (Chemotherapy) 01/2020 - 05/2011
3	Radiotherapy 01/2021 - 08/2009
3	Radioimmunotherapy 10/2020 - 03/2017
2	Precision Medicine 10/2020 - 01/2017
1	Neoadjuvant Therapy 01/2020